Anti-Apolipoprotein E3 抗体 (Biotin) (ab84232)


  • 製品名Anti-Apolipoprotein E3 antibody (Biotin)
    Apolipoprotein E3 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to Apolipoprotein E3 (Biotin)
  • 標識Biotin
  • 特異性ab84232 allows the detection of at least 0.2 – 0.4 ng/well of recombinant human Apolipoprotein EIII in ELISA assays and 1.5 - 3.0 ng/lane in Western blot, under either reducing or non-reducing conditions. Cross reacts with human Apolipoprotein EII and human Apolipoprotien EIV in both western blot and sandwich ELISA.
  • アプリケーション適用あり: WB, ELISA, Sandwich ELISAmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Highly pure (>98%) recombinant human Apolipoprotein EIII

  • ポジティブ・コントロール
    • Recombinant human Apolipoprotein EIII.



Our Abpromise guarantee covers the use of ab84232 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
Sandwich ELISA
  • 追加情報ELISA: Use at a concentration of 0.25 - 1 µg/ml (100 µl/well).
    sELISA: Use at a concentration of 0.25 - 1 µg/ml (100 µl/well).
    WB: Use at a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 35 kDa.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • ターゲット情報

    • 機能Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.
    • 組織特異性Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
    • 関連疾患Defects in APOE are a cause of hyperlipoproteinemia type 3 (HLPP3) [MIM:107741]; also known as familial dysbetalipoproteinemia. Individuals with HLPP3 are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD.
      Genetic variations in APOE are associated with Alzheimer disease type 2 (AD2) [MIM:104310]. It is a late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Note=The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known.
      Defects in APOE are a cause of sea-blue histiocyte disease (SBHD) [MIM:269600]; also known as sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses.
      Defects in APOE are a cause of lipoprotein glomerulopathy (LPG) [MIM:611771]. LPG is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians.
    • 配列類似性Belongs to the apolipoprotein A1/A4/E family.
    • 翻訳後修飾Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. O-glycosylated with core 1 or possibly core 8 glycans. Thr-307 is a minor glycosylation site compared to Ser-308.
      Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold).
      Phosphorylation sites are present in the extracelllular medium.
    • 細胞内局在Secreted.
    • Information by UniProt
    • 参照データベース
    • 別名
      • AD2 antibody
      • Apo-E antibody
      • APOE antibody
      • APOE_HUMAN antibody
      • APOE3 antibody
      • ApoEb antibody
      • Apolipoprotein E antibody
      • Apoprotein antibody
      see all

    Anti-Apolipoprotein E3 antibody (Biotin) (ab84232) 使用論文

    ab84232 has not yet been referenced specifically in any publications.

    Product Wall

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application ELISA
    Sample Human Recombinant protein (ApoEIII, ApoEII human recombinant)
    Specification ApoEIII, ApoEII human recombinant
    Blocking step BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Type Sandwich (Detection)

    Abcam user community

    Verified customer

    投稿 Mar 15 2011